Lewiss on Lifestyle MedicineThe U.S. physical activity guidelines recommend that healthy adults, including elderly, get at least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of ...

In this interview Ira Zackon, MD, highlights data on bispecific antibody use in patients with multiple myeloma in the community setting as presented at ASH 2025.

In this interview Shahzad Raza, MD, discusses a study on the treatment of patients with extramedullary myeloma, as presented at ASH 2025.

In this interview Shahzad Raza, MD, highlights data on CAR T-cell therapies and the use of bispecifics in earlier lines of multiple myeloma as presented at ASH 2025.

In this interview, Ann S. LaCasce, MD, highlights a late-breaking abstract on in vivo CAR T-cell therapy use in multiple myeloma, as presented at ASH 2025.

Calling eye drops “artificial tears” can mislead people into thinking the drops are more sophisticated than they truly are ...

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

The question of whether invasive or noninvasive methods provide the best possible outcomes for patients with ...

ORLANDO — Children and adolescents with food allergy often experience substantial fear of negative social evaluation, ...

Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...

Oral corticosteroids present significant long-term risks with uncertain evidence for improving asthma outcomes, according to data presented at the American College of Allergy, Asthma & Immunology ...

Autoantibody positivity rates were lower in people with dermatomyositis who used immunostimulatory herbs before disease onset ...